Cendakimab
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Target | Interleukin 13 |
| Clinical data | |
| Other names | RPC4046; ABT 308; CC-93538 |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| DrugBank | |
| UNII | |
Cendakimab (RPC4046; ABT 308; CC-93538) is a monoclonal antibody against interleukin 13. It is developed by Bristol Myers Squibb[1] for eosinophilic esophagitis.[2][3][4]
References
[edit]- ^ "Pharmaceutical Research & Development Pipeline - Bristol Myers Squibb". www.bms.com. Retrieved 4 December 2023.
- ^ Syverson EP, Hait E (April 2022). "Update on Emerging Pharmacologic Therapies for Patients With Eosinophilic Esophagitis". Gastroenterology & Hepatology. 18 (4): 207–212. ISSN 1554-7914. PMC 9053490. PMID 35505944.
- ^ Caldwell J, Ballaban A, Li J, Maddux R, Harris S, Rothenberg M (February 2023). "Anti–IL-13 (cendakimab) administration improves esophageal gene expression in eosinophilic esophagitis". Journal of Allergy and Clinical Immunology. 151 (2): AB215. doi:10.1016/j.jaci.2022.12.670. S2CID 256589074.
- ^ Hirano I, Collins MH, Assouline-Dayan Y, Evans L, Gupta S, Schoepfer AM, et al. (February 2019). "RPC4046, a Monoclonal Antibody Against IL13, Reduces Histologic and Endoscopic Activity in Patients With Eosinophilic Esophagitis". Gastroenterology. 156 (3): 592–603.e10. doi:10.1053/j.gastro.2018.10.051. PMID 30395812.
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |